Estimation of the Impact of Noncompliance on Pharmacokinetics: an Analysis of the Influence of Dosing Regimens

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2008 Apr 4

PMID 18384445

Citations 3

Authors

Dyfrig A Hughes

Affiliations

Soon will be listed here.

Abstract

What Is Already Known About This Subject: Patient compliance is better with formulations that require less frequent dosing than with formulations that require more frequent dosing. Intramuscular risperidone and long-acting oxybutynin are two examples of medicines reformulated for less frequent dosing. However, it is not clear whether better compliance with less frequent dosing regimens translates to improved therapeutic outcome.

What This Study Adds: At equivalent daily doses and typical patterns of compliance, fortnightly intramuscular depot administrations of risperidone provide better pharmacokinetic coverage than once-daily oral dosing. Once-daily dosing of oxybutynin is no better at maintaining pharmacokinetic exposure than twice-daily dosing at half strength. The use of simulated compliance data as input to pharmacokinetic models is useful to assess the impact of noncompliance on internal drug exposure.

Aims: To determine whether, for oxybutynin and risperidone, drug exposure is better with less frequent dosing regimens than with regimens that require more frequent dosing.

Methods: Pharmacokinetic models of oxybutynin (5 mg twice-daily and 10 mg once-daily) and risperidone (2 mg once-daily orally and 25 mg fortnightly intramuscular injection) were developed. Simulations of multiple doses were performed by use of stochastic models of dose-taking compliance and clinic visit attendance.

Results: At therapeutic concentrations and with typical patterns of noncompliance, intramuscular injections of risperidone resulted in a 41% (SD 12%) greater pharmacokinetic coverage than the oral dose, 76% (SD 10%) vs. 35% (SD 7%). No discernable differences were evident between once- and twice-daily formulations of oxybutynin, 29.2% (SD 10%) vs. 29.0% (SD 13%).

Conclusions: For equivalent doses for each drug, the longer acting preparation of risperidone, but not oxybutynin, is pharmacokinetically more forgiving of noncompliance than the shorter acting counterparts. Further analysis is required to confirm whether these observations are valid clinically.

Citing Articles

Regularity of self-reported daily dosage of mood stabilizers and antipsychotics in patients with bipolar disorder.

Pilhatsch M, Glenn T, Rasgon N, Alda M, Sagduyu K, Grof P Int J Bipolar Disord. 2018; 6(1):10.

PMID: 29713845 PMC: 6161976. DOI: 10.1186/s40345-018-0118-8.

Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.

Sajatovic M, Levin J, Ramirez L, Hahn D, Tatsuoka C, Bialko C J Clin Psychiatry. 2014; 74(12):1249-55.

PMID: 24434094 PMC: 4129952. DOI: 10.4088/JCP.12m08331.

Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.

Zhornitsky S, Stip E Schizophr Res Treatment. 2012; 2012:407171.

PMID: 22966436 PMC: 3420751. DOI: 10.1155/2012/407171.

References

Tauscher J, Jones C, Remington G, Zipursky R, Kapur S . Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry. 2002; 7(3):317-21. DOI: 10.1038/sj.mp.4001009. View

Velligan D, Lam Y, Glahn D, Barrett J, Maples N, Ereshefsky L . Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull. 2006; 32(4):724-42. PMC: 2632258. DOI: 10.1093/schbul/sbj075. View

Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L . Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2004; 15(1):111-7. DOI: 10.1016/j.euroneuro.2004.07.003. View

Claxton A, Cramer J, Pierce C . A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001; 23(8):1296-310. DOI: 10.1016/s0149-2918(01)80109-0. View

Nony P, Cucherat M, Boissel J . Revisiting the effect compartment through timing errors in drug administration. Trends Pharmacol Sci. 1998; 19(2):49-54. DOI: 10.1016/s0165-6147(97)01159-0. View

Lee D, Lee K, Kwon J, Jang I, Cho M, Shin S . Pharmacokinetic-pharmacodynamic modeling of risperidone effects on electroencephalography in healthy volunteers. Psychopharmacology (Berl). 1999; 144(3):272-8. DOI: 10.1007/s002130051003. View

Megens A, Awouters F, SCHOTTE A, Meert T, Dugovic C, NIEMEGEERS C . Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994; 114(1):9-23. DOI: 10.1007/BF02245439. View

Boissel J, Nony P . Using pharmacokinetic-pharmacodynamic relationships to predict the effect of poor compliance. Clin Pharmacokinet. 2002; 41(1):1-6. DOI: 10.2165/00003088-200241010-00001. View

Levy G, Zamacona M, Jusko W . Developing compliance instructions for drug labeling. Clin Pharmacol Ther. 2001; 68(6):586-91. DOI: 10.1067/mcp.2000.110976. View

10.

Sathyan G, Chancellor M, Gupta S . Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol. 2001; 52(4):409-17. PMC: 2014596. DOI: 10.1046/j.0306-5251.2001.01463.x. View

11.

Waldeck K, Larsson B, Andersson K . Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol. 1997; 157(3):1093-7. View

12.

Comte L, Vrijens B, Tousset E, Gerard P, Urquhart J . Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. J Pharmacokinet Pharmacodyn. 2007; 34(4):549-58. DOI: 10.1007/s10928-007-9058-0. View

13.

Sparr L, Moffitt M, Ward M . Missed psychiatric appointments: who returns and who stays away. Am J Psychiatry. 1993; 150(5):801-5. DOI: 10.1176/ajp.150.5.801. View

14.

Blesius A, Chabaud S, Cucherat M, Mismetti P, Boissel J, Nony P . Compliance-guided therapy : a new insight into the potential role of clinical pharmacologists. Clin Pharmacokinet. 2006; 45(1):95-104. DOI: 10.2165/00003088-200645010-00007. View

15.

Gupta S, Sathyan G, Lindemulder E, Ho P, Sheiner L, Aarons L . Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. Clin Pharmacol Ther. 1999; 65(6):672-84. DOI: 10.1016/S0009-9236(99)90089-9. View

16.

Mannaert E, Vermeulen A, Remmerie B, Bouhours P, Levron J . Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration. Encephale. 2006; 31(5 Pt 1):609-15. DOI: 10.1016/s0013-7006(05)82420-0. View

17.

Pitsiu M, Sathyan G, Gupta S, Verotta D . A semiparametric deconvolution model to establish in vivo-in vitro correlation applied to OROS oxybutynin. J Pharm Sci. 2001; 90(6):702-12. DOI: 10.1002/jps.1026. View

18.

Gefvert O, Eriksson B, Persson P, Helldin L, Bjorner A, Mannaert E . Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol. 2005; 8(1):27-36. DOI: 10.1017/S1461145704004924. View

19.

Remington G, Kwon J, Collins A, Laporte D, Mann S, Christensen B . The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res. 2007; 90(1-3):229-37. DOI: 10.1016/j.schres.2006.11.015. View

20.

Girard P, Blaschke T, Kastrissios H, Sheiner L . A Markov mixed effect regression model for drug compliance. Stat Med. 1998; 17(20):2313-33. DOI: 10.1002/(sici)1097-0258(19981030)17:20<2313::aid-sim935>3.0.co;2-v. View